Unmasking "Bone Loss": Beyond the Bone Density Myths

Ladies, let's talk about our bones. As we navigate the incredible journey of life between 40 and 65, the topic of bone density often comes up, sometimes with a cloud of confusion and even fear. We're bombarded with terms like "osteoporosis" and "osteopenia," often leading to anxiety and a rush to medication. But what if much of what we've been told is based on a narrative that doesn't tell the whole truth? It's time to bust some myths about "boss loss" – our bone strength – and empower ourselves with clearer information.

For too long, the narrative around bone density has been driven by a single number: the bone density scan (DXA) T-score. When this score dips below -2.5, you're often given an "artificial diagnosis" of osteoporosis. This threshold, while seemingly scientific, is set against the bone density of a healthy 30-year-old.

Now, if -2.5 is deemed "bad," it logically follows that -1.5 might be "a little bad," right? This thinking led to the creation of the term "osteopenia." But here's where it gets interesting: according to epidemiologist Stephen Cummings, who has conducted extensive large-scale studies, the term osteopenia has no medical meaning. Yes, you read that correctly.

The "30-Year-Old" Trap: Why Your Score is Misleading

To understand why experts like Stephen Cummings call these diagnoses "artificial," we have to look at the yardstick being used. When you get a DXA scan, your bones aren't being compared to other healthy women your age; they are being compared to the "peak bone mass" of a healthy 30-year-old.

Imagine if we graded everyone’s eyesight by comparing it to the 20/20 vision of a young fighter pilot. By that logic, almost every woman over 50 would be diagnosed with "Visual Failure" and told she needs intensive treatment.

In 1994, when the World Health Organization (WHO) sat down to define osteoporosis, they chose the -2.5 cut-off somewhat arbitrarily. They needed a line in the sand, but there is no biological "cliff" at that number. A woman with a score of -2.4 is told she is "safe" (merely osteopenic), while a woman with -2.6 is told she has a "disease."

In reality, the research shows that the majority of hip fractures actually occur in women who have scores above -2.5. This proves that the density (the amount of mineral) isn't the whole story—it's the resilience (the quality and flexibility of the bone) that truly matters.

The Rise of "Osteopenia": A Marketing Masterpiece?

If you’ve been told you have "osteopenia," you might feel like you’re standing on the edge of a cliff. But here is the industry secret: the term osteopenia has no medical meaning. Stephen Cummings, the renowned epidemiologist, has been vocal about this for years. So why does every doctor’s office use it? The answer lies in the intersection of medicine and "Big Pharma."

When DXA scanning technology became widely available, pharmaceutical companies saw a massive opportunity to expand their market. By taking a natural, age-related decline in bone density and labeling it as a "pre-disease" state, they effectively turned millions of healthy women into "patients."

Big Pharma Wanting In

The pharmaceutical industry didn't just want to treat the small percentage of women with severe osteoporosis; they wanted "in" on the much larger population of women aged 40 to 65. By promoting the use of the term osteopenia, they created a justification for prescribing bisphosphonates (like Fosamax) to women who likely would never have suffered a fracture.

This is often referred to as "disease mongering." By lowering the threshold of what is considered "normal," the industry essentially medicalized the aging process to ensure a steady stream of prescriptions. For the drug companies, your natural bone aging wasn't a phase of life—it was a market share.

The Bisphosphonate Conundrum: Unpleasant Truths

The medications often prescribed for low bone density, known as bisphosphonates (like Fosamax), come with a host of unpleasant side effects. In fact, 70% of women stop taking them within a year due to these issues. Imagine dealing with gastrointestinal discomfort, insomnia, fatigue, and even kidney problems.

Even more concerning, long-term use of these medications can increase the risk of an atypical hip fracture – a different kind of break than the typical hip fracture associated with osteoporosis. This is a stark contrast to how our bodies naturally build bone.

Here's the kicker: while estrogen naturally facilitates normal bone building, bisphosphonates are associated with an excess of bone mineralization. Think of it like building a house with brittle, over-hardened bricks. They might look dense, but they lack the flexibility and resilience needed to withstand stress.

Many bisphosphonates, like Fosamax, were approved quickly by the FDA, meaning a lack of long-term trials and data. And surprisingly, after a year of taking them, the bone mineral density often returns to its normal baseline.

Exercise, Calcium, and Vitamin D: Not Always the Magic Bullet

We're often told to exercise and supplement with calcium and vitamin D to prevent bone loss. While exercise is undoubtedly crucial for overall health, and it can improve bone strength and fracture resistance in premenopausal women, studies show it does not improve bone density among postmenopausal women who are not taking HRT.

Similarly, while calcium and vitamin D are important nutrients, they are often ineffective in preventing postmenopausal osteoporosis or even fractures. Why? Because they don't affect bone resilience, which is the "snapping point" of our bones – their ability to bend and absorb impact without breaking.

Estrogen: The True "Boss" of Bone Health

So, what does truly make a difference for bone resilience and strength, especially after menopause? The answer, as highlighted in "Estrogen Matters" by Avrum Bluming, is often estrogen.

Estrogen plays a pivotal role in maintaining healthy, resilient bones. It's not just about density; it's about the quality and structure of the bone itself. When estrogen levels decline significantly during menopause, our bones become more vulnerable.

While Hormone Replacement Therapy (HRT) isn't the answer for every woman, the research is compelling. Numerous studies show that if you are taking HRT post-menopausally, you are likely to have stronger and more resilient bones. This means bones that are not just dense, but also have the flexibility and integrity to resist fractures.

Instead of solely focusing on a potentially misleading T-score or relying on medications with significant side effects, it's crucial to understand the foundational role of estrogen in bone health. For many women, particularly those considering their options post-menopause, exploring the benefits of estrogen in consultation with a knowledgeable healthcare provider could be a game-changer for long-term bone strength and overall well-being.

It's time to take back control of our bone health narrative. Educate yourself, ask questions, and advocate for treatments that truly address the root causes of bone loss, not just the symptoms.

Bibliography & References:

·        Bluming, A., & Tavris, C. (2018). Estrogen Matters: Why Taking Hormones in Menopause Can Improve as Well as Prolong Women's Lives. Little, Brown Spark.

·        Cummings, S. R., et al. (2002). "The diagnosis of osteoporosis." Journal of the American Medical Association (JAMA).

·        Alonso-Coello, P., et al. (2008). "Drugs for pre-osteoporosis: prevention or medicalisation?" BMJ. (Discussing the pharmaceutical role in the creation of 'osteopenia').

·        Moynihan, R., & Cassels, A. (2005). Selling Sickness: How the World's Biggest Pharmaceutical Companies Are Turning Us All Into Patients. Greystone Books.

·        FDA Safety Communications: Regarding long-term bisphosphonate use and the associated risks of atypical fractures and jaw issues.